Can't say what is going on now, but some background history for...

Can't say what is going on now, but some background history for recent investors:

Dimerix undertook initial phase 2 trials for DMX-200 for treatment of both the rare condition FSGS, and the much more common Diabetic Kidney Disease (DKD). These trials produced positive results for both conditions, and thus Dimerix proceeded to a more detailed Phase 2 trial in both conditions. Disappointingly, while the results from this trial (late August 2020) were positive for FSGS, it was not deemed statistically significant for the DKD arm. This was disappointing, and there was some conversations at the time as to whether this could have been the result of a quite complicated trial design, but a result is a result.

So it is good that there is continuing work on potential for DMX-200 treatment of DKD. Trial expected to complete sometime in the next 12 months, so hopefully no news is good news!